Autologous transplant of follicular lymphoma in the era of rituximab

References

• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–2795.
   PubMed Web of Science ®Google Scholar
• Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240–1251.
   PubMed Web of Science ®Google Scholar
• Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin.Lymphoma 2003;4:161–168.
   PubMedGoogle Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106–114.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204–210.
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, et al Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.
   PubMed Web of Science ®Google Scholar
• Rummel M, Niederle N, Maschmeyer G. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase iii study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114(Suppl. 1): (Abstract 405).
   Google Scholar
• Morschhauser F, Radford J, van HA, et al Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
   PubMed Web of Science ®Google Scholar
• Apostolidis J, Gupta RK, Grenzelias D, et al High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000;18:527–536.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Freedman AS, Neuberg D, et al Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525–1533.
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Vose JM, Anderson JR, et al High-dose therapy with autologous hematopoietic rescue for follicular low-grade Non-Hodgkin's lymphoma. J Clin Oncol 1997;15:445–450.
   PubMed Web of Science ®Google Scholar
• Freedman AS, Neuberg D, Mauch P, et al Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325–3333.
   PubMed Web of Science ®Google Scholar
• Brice P, Simon D, Bouabdallah R, et al High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000;11:1585–1590.
   PubMed Web of Science ®Google Scholar
• Rohatiner AZ, Nadler L, Davies AJ, et al Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007;25:2554–2559.
   PubMed Web of Science ®Google Scholar
• Schouten HC, Qian W, Kvaloy S, et al High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918–3927.
   PubMed Web of Science ®Google Scholar
• Kornacker M, Stumm J, Pott C, et al Characteristics of relapse after autologous stem cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 2009;20:722–728.
   PubMed Web of Science ®Google Scholar
• Montoto S, Canals C, Rohatiner AZ, et al Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007;21:2324–2331.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, et al Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma – results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2004;104:2667–2674.
   PubMed Web of Science ®Google Scholar
• Gyan E, Foussard C, Bertrand P, et al High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009;113:995–1001.
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, et al Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006;108:2540–2544.
   PubMed Web of Science ®Google Scholar
• Ladetto M, De Marco F, Benedetti F, et al Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008;111:4004–4013.
   PubMed Web of Science ®Google Scholar
• Brown JR, Feng Y, Gribben JG, et al Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007;13:1057–1065.
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Zallio F, et al Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004;22:1460–1468.
   PubMed Web of Science ®Google Scholar
• Hicks LK, Woods A, Buckstein R, et al Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009;43:701–708.
   PubMed Web of Science ®Google Scholar
• Vose JM, Bierman PJ, Loberiza FR, et al Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008;14:36–42.
   PubMed Web of Science ®Google Scholar
• Leger CS, Bredeson C, Kearns B, et al Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000;6:204–210.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Gooley TA, Golden JB, et al Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001;27:593–599.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Rambaldi A, et al Autologous stem cell transplantation in elderly patients (> = 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008;93:1837–1842.
   PubMed Web of Science ®Google Scholar
• Buadi FK, Micallef IN, Ansell SM, et al Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006;37:1017–1022.
   PubMed Web of Science ®Google Scholar
• Tucci A, Ferrari S, Bottelli C, et al A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009;115:4547–4553.
   PubMed Web of Science ®Google Scholar
• Brown JR, Yeckes H, Friedberg JW, et al Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005;23:2208–2214.
   PubMed Web of Science ®Google Scholar
• Seyfarth B, Kuse R, Sonnen R, et al Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? Ann Hematol 2001;80:398–405.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Hsu Schmitz G, Martinelli G, et al Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. J Clin Oncol 2009;27(Suppl.): 15s (Abstract 8512).
   Google Scholar
• Maloney DG, Grillo LA, White CA, et al IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188–2195.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Feuring-Buske M, Kneba M, Unterhalt M, et al IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000;79:493–500.
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N, et al Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101–106.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711–4716.
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S et al Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824–4831.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone – results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579–4586.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, et al The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064–3071.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, et al Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, et al Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416–4423.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003–4008.
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, et al Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009;27:1607–1614.
   PubMed Web of Science ®Google Scholar
• Sebban C, Brice P, Delarue R, et al Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:3614–3620.
   PubMed Web of Science ®Google Scholar
• Weigert O, Uysal A, Metzner B, et al Impact of autologous stem cell transplantation and/or rituximab in patients with relapsed follicular lymphoma – retrospective analysis of 2 randomized trials of the German Low Grade Lymphoma Study Group (GLSG). Blood 2008;114(Suppl. 1): (Abstract 2189).
   PubMed Web of Science ®Google Scholar
• Le Gouill S, de Guibert S, Volteau C, et al Autologous stem cell transplantation (auto-SCT) as the treatment of choice for follicular lymphoma patients in first relapse: final analysis of the outcome of 175 patients treated in the GELA/GOELAMS FL 2000 Study. Blood 2008;112(Suppl. 1): (Abstract 773).
   Google Scholar
• Sebban C, Brice P, Delarue R, et al Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:3614–3620.
   PubMed Web of Science ®Google Scholar
• Rezvani AR, Storer B, Maris M, et al Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008;26:211–217.
   PubMed Web of Science ®Google Scholar
• Khouri IF, McLaughlin P, Saliba RM, et al Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008;111:5530–5536.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Dreger P, Glass B, Sureda A. Allogeneic transplantation in lymphoma: current status. Haematologica 2007;92:1533–1548.
   PubMed Web of Science ®Google Scholar
• Apostolidis J, Foran JM, Johnson PWM, et al Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1999;17:216–221.
   PubMed Web of Science ®Google Scholar
• Seyfarth B, Josting A, Dreyling M, Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol 2006;133:3–18.
   PubMed Web of Science ®Google Scholar